CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.5860
6.49%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0280
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

GlycoMimetics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.696
Open* 1.716
1-Year Change* -22.96%
Day's Range* 1.526 - 1.716
52 wk Range 1.11-4.16
Average Volume (10 days) 84.80K
Average Volume (3 months) 2.51M
Market Cap 96.59M
P/E Ratio -100.00K
Shares Outstanding 64.39M
Revenue N/A
EPS -0.64
Dividend (Yield %) N/A
Beta 2.08
Next Earnings Date Mar 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 1.6960 0.0900 5.60% 1.6060 1.7160 1.5960
Nov 30, 2023 1.6360 0.1400 9.36% 1.4960 1.6460 1.4860
Nov 29, 2023 1.4960 0.0000 0.00% 1.4960 1.5460 1.4960
Nov 28, 2023 1.5160 0.0300 2.02% 1.4860 1.5160 1.4460
Nov 27, 2023 1.5160 -0.0700 -4.41% 1.5860 1.5860 1.5160
Nov 24, 2023 1.5260 0.0100 0.66% 1.5160 1.5860 1.4660
Nov 22, 2023 1.4760 0.0200 1.37% 1.4560 1.5160 1.3760
Nov 21, 2023 1.4660 0.0200 1.38% 1.4460 1.4960 1.4460
Nov 20, 2023 1.5060 0.0600 4.15% 1.4460 1.5460 1.4460
Nov 17, 2023 1.3960 0.1300 10.27% 1.2660 1.4360 1.2460
Nov 16, 2023 1.3260 0.0000 0.00% 1.3260 1.3860 1.2560
Nov 15, 2023 1.3460 0.0000 0.00% 1.3460 1.4360 1.2960
Nov 14, 2023 1.3260 0.0400 3.11% 1.2860 1.3560 1.2360
Nov 13, 2023 1.2960 0.1000 8.36% 1.1960 1.3160 1.1660
Nov 10, 2023 1.1760 -0.0400 -3.29% 1.2160 1.2160 1.1660
Nov 9, 2023 1.1860 -0.1200 -9.19% 1.3060 1.3360 1.1560
Nov 8, 2023 1.3160 -0.0200 -1.50% 1.3360 1.3560 1.2860
Nov 7, 2023 1.3360 0.0400 3.09% 1.2960 1.4060 1.2760
Nov 6, 2023 1.3260 0.0200 1.53% 1.3060 1.3360 1.2960
Nov 3, 2023 1.3360 0.0100 0.75% 1.3260 1.3460 1.2760

GlycoMimetics Events

Time (UTC) Country Event
Wednesday, March 27, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 GlycoMimetics Inc Earnings Release
Q4 2023 GlycoMimetics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0.075 1.15977 10.1629 0 0
Revenue 0.075 1.15977 10.1629 0 0
Total Operating Expense 47.4783 64.607 61.6723 61.3893 51.5048
Selling/General/Admin. Expenses, Total 19.0874 17.1154 16.7431 14.36 11.413
Research & Development 28.3909 47.4916 44.9292 47.0293 40.0918
Operating Income -47.4033 -63.4472 -51.5094 -61.3893 -51.5048
Interest Income (Expense), Net Non-Operating 0.71452 0.01977 0.48249 3.49739 3.23119
Net Income Before Taxes -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Net Income After Taxes -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Net Income Before Extra. Items -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Net Income -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Income Available to Common Excl. Extra. Items -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Income Available to Common Incl. Extra. Items -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Diluted Net Income -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Diluted Weighted Average Shares 52.5312 51.4532 45.7211 43.2548 41.0446
Diluted EPS Excluding Extraordinary Items -0.88878 -1.23272 -1.11605 -1.33839 -1.17613
Diluted Normalized EPS -0.88878 -1.23272 -1.11605 -1.33839 -1.17613
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0.075
Revenue 0 0 0 0.075
Total Operating Expense 8.92995 10.941 10.6226 8.76744 13.4282
Selling/General/Admin. Expenses, Total 4.85724 5.52231 4.7318 3.84458 5.45488
Research & Development 4.07271 5.41871 5.89082 4.92286 7.97328
Operating Income -8.92995 -10.941 -10.6226 -8.76744 -13.3532
Interest Income (Expense), Net Non-Operating 0.67103 0.58167 0.37827 0.2436 0.08559
Net Income Before Taxes -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Net Income After Taxes -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Net Income Before Extra. Items -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Net Income -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Income Available to Common Excl. Extra. Items -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Income Available to Common Incl. Extra. Items -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Diluted Net Income -8.25891 -10.3594 -10.2444 -8.52384 -13.2676
Diluted Weighted Average Shares 64.2762 60.3501 52.962 52.4239 52.4073
Diluted EPS Excluding Extraordinary Items -0.12849 -0.17165 -0.19343 -0.16259 -0.25316
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.12849 -0.17165 -0.19343 -0.16259 -0.25316
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 50.7147 90.7887 138.273 162.528 212.269
Cash and Short Term Investments 47.8706 90.2549 137.035 158.201 209.918
Cash & Equivalents 47.8706 90.2549 137.035 158.201 209.918
Short Term Investments
Total Receivables, Net 0.14402 0.00135 0.00215 0.18595 0.41312
Prepaid Expenses 2.70007 0.53246 1.23618 4.14037 1.9384
Total Assets 51.8106 94.3466 142.832 167.97 214.839
Property/Plant/Equipment, Total - Net 0.99356 1.94503 2.9459 3.82899 0.95723
Property/Plant/Equipment, Total - Gross 3.38018 4.26792 5.0782 5.69053 2.54087
Accumulated Depreciation, Total -2.38662 -2.3229 -2.1323 -1.86155 -1.58364
Other Long Term Assets, Total 0.10232 1.61293 1.61293 1.61293 1.61293
Total Current Liabilities 8.88075 11.8244 12.4284 10.9506 8.76315
Accounts Payable 0.97019 2.10762 2.08994 1.43566 2.66358
Accrued Expenses 7.91056 9.71678 10.3384 9.51492 6.0008
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.09877
Total Liabilities 8.88075 12.743 14.6127 13.7691 9.37478
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0.91861 2.18434 2.81852 0.61162
Total Equity 42.9298 81.6037 128.219 154.201 205.464
Preferred Stock - Non Redeemable, Net 0 0
Common Stock 0.05438 0.05231 0.04902 0.04347 0.04316
Additional Paid-In Capital 462.461 454.448 437.64 412.6 405.972
Retained Earnings (Accumulated Deficit) -419.586 -372.897 -309.47 -258.443 -200.551
Total Liabilities & Shareholders’ Equity 51.8106 94.3466 142.832 167.97 214.839
Total Common Shares Outstanding 54.3778 52.3139 49.0176 43.4669 43.1608
Total Preferred Shares Outstanding
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 52.0101 60.3688 68.0865 50.7147 53.8482
Cash and Short Term Investments 49.4076 58.0371 65.0023 47.8706 51.6248
Cash & Equivalents 49.4076 58.0371 65.0023 47.8706 51.6248
Total Receivables, Net 0.18895 0.21537 0.23411 0.14402 0.09033
Prepaid Expenses 2.4135 2.11639 2.85008 2.70007 2.13309
Total Assets 53.2007 61.8215 68.9217 51.8106 55.9614
Property/Plant/Equipment, Total - Net 1.08829 1.35036 0.7328 0.99356 1.25313
Property/Plant/Equipment, Total - Gross 3.59843 3.81775 3.16326 3.38018 3.59403
Accumulated Depreciation, Total -2.51014 -2.46739 -2.43045 -2.38662 -2.3409
Other Long Term Assets, Total 0.10232 0.10232 0.10232 0.10232 0.86012
Total Current Liabilities 6.39088 6.572 6.74021 8.88075 7.74825
Accounts Payable 0.32989 0.24149 0.48015 0.97019 0.85213
Accrued Expenses 6.061 6.33052 6.26006 7.91056 6.89613
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 6.65301 7.02078 6.74021 8.88075 7.84386
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.26213 0.44878 0 0.09561
Total Equity 46.5477 54.8007 62.1814 42.9298 48.1176
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.06437 0.06431 0.06425 0.05438 0.05242
Additional Paid-In Capital 493.89 492.94 492.062 462.461 457.407
Retained Earnings (Accumulated Deficit) -447.407 -438.204 -429.945 -419.586 -409.341
Total Liabilities & Shareholders’ Equity 53.2007 61.8215 68.9217 51.8106 55.9614
Total Common Shares Outstanding 64.3688 64.3133 64.2452 54.3778 52.4239
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -46.6888 -63.4274 -51.0269 -57.8919 -48.2736
Cash From Operating Activities -46.4575 -57.4895 -39.2419 -51.9841 -43.3311
Cash From Operating Activities 0.20715 0.2646 0.27075 0.27923 0.27512
Non-Cash Items 4.68609 6.8385 7.5826 6.83516 4.58727
Cash Taxes Paid
Changes in Working Capital -4.66192 -1.16519 3.93162 -1.20662 0.08011
Cash From Investing Activities -0.08419 -0.01494 -0.06851 -0.14493 -0.12562
Capital Expenditures -0.08419 -0.01494 -0.06851 -0.14493 -0.12562
Cash From Financing Activities 4.15741 10.7243 18.144 0.41291 129.45
Issuance (Retirement) of Stock, Net 4.15741 10.7243 18.144 0.41291 129.45
Net Change in Cash -42.3843 -46.7801 -21.1664 -51.7161 85.9929
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -10.3594 -46.6888 -36.4445 -27.9206 -14.653
Cash From Operating Activities -11.6069 -46.4575 -38.5459 -29.9288 -13.6981
Cash From Operating Activities 0.04384 0.20715 0.16143 0.11408 0.05931
Non-Cash Items 1.0893 4.68609 3.57304 2.45038 1.27946
Changes in Working Capital -2.38065 -4.66192 -5.83594 -4.57266 -0.38387
Cash From Investing Activities -0.0022 -0.08419 -0.08419 -0.08171 -0.04052
Capital Expenditures -0.0022 -0.08419 -0.08419 -0.08171 -0.04052
Cash From Financing Activities 28.7408 4.15741 0 0 0
Issuance (Retirement) of Stock, Net 28.7408 4.15741 0 0 0
Net Change in Cash 17.1317 -42.3843 -38.6301 -30.0105 -13.7387
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BVF Partners L.P. Hedge Fund 14.8396 9544262 0 2023-06-30 LOW
Invus Public Equities Advisors, LLC Investment Advisor 13.3544 8589064 0 2023-06-30 MED
New Enterprise Associates (NEA) Venture Capital 7.4078 4764440 0 2023-06-30 LOW
Octagon Capital Advisors LP Hedge Fund 4.6644 3000000 0 2023-06-30 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.5985 2314405 -146428 2023-06-30 LOW
AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund 2.5367 1631509 22448 2023-06-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.7875 1149656 -251997 2023-06-30 MED
Goldman Sachs & Company, Inc. Research Firm 1.2186 783731 -118160 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.1909 765953 124925 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 1.0135 651814 -313255 2023-06-30 HIGH
King (Rachel K) Individual Investor 0.9409 605139 6667 2023-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7405 476240 70905 2023-06-30 LOW
Rock (Edwin) Individual Investor 0.5837 375403 65403 2023-09-22 LOW
Magnani (John L) Individual Investor 0.5365 345048 45045 2022-11-11
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2904 186765 0 2023-06-30 LOW
Rath (Chinmaya) Individual Investor 0.2506 161178 161178 2023-03-23
Connor, Clark & Lunn Investment Management Ltd. Investment Advisor/Hedge Fund 0.2428 156191 -2810 2023-06-30 MED
Marshall Wace LLP Investment Advisor/Hedge Fund 0.2214 142400 -73899 2023-06-30 HIGH
Johnson (Bruce S) Individual Investor 0.2161 138980 13500 2023-05-08 LOW
Bridgeway Capital Management, LLC Investment Advisor 0.2113 135900 25500 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

GlycoMimetics Company profile

About GlycoMimetics Inc

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of novel glycomimetic. Its drug candidates include Uproleselan, GMI-1359, Rivipansel, GMI-1687, and Galectin Antagonists. Its Uproleselan a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), a life-threatening hematologic cancer, and potentially other hematologic cancers. The GMI-1359 targets E-selectin and a chemokine receptor. Its Rivipansel is a glycomimetic drug candidate that act as , a pan-selectin antagonist for treatment of vaso-occlusive crisis. It has designed antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. Galectin Antagonists includes Galectin-3, which is a carbohydrate-binding protein.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, GlycoMimetics Inc revenues decreased 89% to $1.2M. Net loss increased 24% to $63.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expenses increase of 8% to $45.3M (expense), Interest income decrease of 96% to $20K (income).

Equity composition

Common Stock, $0.001 Par, 100M Auth shares, 17,555,497 issd,. Insiders Owns approx. 10.08%.

Industry: Bio Therapeutic Drugs

9708 Medical Center Drive
ROCKVILLE
MARYLAND 20850
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

73.37 Price
-1.470% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee -0.0019%
Overnight fee time 22:00 (UTC)
Spread 0.040

BTC/USD

41,800.65 Price
+5.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,034.27 Price
-1.820% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.62 Price
-0.680% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading